Network Version
Maxacalcitol Data Sheet
| Product Name: | Maxacalcitol |
 |
|---|---|---|
| CAS No.: | 103909-75-7 | |
| Cat. No.: | HY-32339 | |
| MWt: | 418.61 | |
| Formula: | C26H42O4 | |
| Purity : | >98% | |
| Solubility: | DMSO : 50 mg/mL (ultrasonic) | |
| Mechanisms: | Target: Endocrinology Inflammation/Immunology Metabolic Disease | |
| Biological Activity: | ||
|
Maxacalcitol (22-Oxacalcitriol), a vitamin D3 (HY-15398) analog, is an orally active VDR agonist. Maxacalcitol has a limited calcemic effect. Maxacalcitol has the potential for psoriasis and hyperparathyroidism research[1][2][3].
In Vitro:Maxacalcitol (22-Oxacalcitriol; 100 nM; for 24 h) markedly increases the expression of LL-37 mRNA in Ca9-22 cells and modestly but significantly increases in HSC-2, HSC-3, and HSC-4 cells[1].
In Vivo:Maxacalcitol (22-Oxacalcitriol; oral gavage; 15 µg/kg/day; 14 days) followed by GSK 269962 at a single dose of 10 mg/kg, leads to a statistically significant reduction of intercontraction interval and bladder compliance, and an increase in DO index, without any effect on ANVC, FNVC, and VTNVC[2]. Maxacalcitol in a dose of 30 but not 15 µg/kg/day induced reduction in detrusor overactivity (DO) index, non-voiding contractions frequency (FNVC), and amplitude (ANVC), while increasing volume threshold to elicit non-voiding contractions (VTNVC)[2]. |
||
1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com